Westlake Village BioPartners is pleased to have seeded and been a major contributor to the Series A funding round for programmable cell therapy company Arsenal Biosciences. The company will integrate technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies, initially for cancer.
At the recent Healthcare Businesswomen’s Association meeting, several themes emerged as essential ingredients in building the Los Angeles biotech hub. Westlake Village BioPartners’ managing director Sean Harper participated in a panel discussion that examined the issues facing Los Angeles as it grows its life sciences industry. The event, titled “Los Angeles: The Next Major Biotechnology … Read More
Los Angeles has a long history of reinventing itself. From a village of 5,000 people in the 1870s, focused on cattle farming and agriculture; to establishing ports, railways, banks and factories designed to challenge San Francisco; to producing one-quarter of the world’s total oil supply by 1923; to the boomtown days of Hollywood from 1913-1941; … Read More
At the recent Yale University Innovation Summit, Westlake Village BioPartners managing director Sean Harper presented an overview of the current advances in life sciences, his views on what is happening in the biotech venture capital world right now, and also provided some advice to entrepreneurs on how to build a successful business. As part of … Read More
Recently, Beth Seidenberg made news at the Fortune Brainstorm Health conference, revealing that cell therapy startup Tmunity has brought a product into human clinical trials that has knocked out multiple cancer genes.
Today Forbes announced that Westlake Village BioPartners founding managing director Beth Seidenberg, MD, has been ranked 59 on the annual Midas List of the world’s top 100 technology venture capitalists.
Building a company from scratch can be exciting and rewarding and if you do it right you can change the world. However, it can also be challenging and is fraught with risk. While some venture capital firms are primarily focused on financials, at Westlake Village BioPartners our philosophy is to build world-class companies by taking a different approach.
Recently, the San Fernando Valley Business Journal reported on what Westlake Village BioPartners is doing in the greater Los Angeles area to establish a life sciences hub. It is exciting to know we are playing our part catalyzing the industry in this region!
We are sprinting into what we believe is the Golden Age of Biotechnology—and the implications for humanity are profound. Just like in other industries in the past, such as aerospace and computing, we are now at an inflection point in biotechnology where we can address the most fundamental of human concerns: how to live longer, healthier lives, free of disease.
Westlake Village BioPartners, a new venture firm exclusively focused on investing in life sciences, announced the launch of the firm’s first fund with $320 million of committed capital.